PMA supplement
P180011 S024: Eluvia Drug-Eluting Vascular Stent System
FDA PMA supplement · Normal 180 Day Track No User Fee · Boston Scientific Corp
Key facts
| Original PMA | P180011 |
|---|---|
| Supplement number | S024 |
| Supplement type | Normal 180 Day Track No User Fee |
| Reason for the supplement | Postapproval Study Protocol |
| Trade name | Eluvia Drug-Eluting Vascular Stent System |
| Generic name | Stent, superficial femoral artery, drug-eluting |
| Applicant | Boston Scientific Corp |
| Product code | NIU |
| Received date | Jan 21, 2020 |
| Decision date | Apr 1, 2020 |
At a glance
- No Expedited review granted
- No Approval order on file
- No Summary of safety and effectiveness on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMA supplements
A PMA supplement asks FDA to approve a change to a device that already holds a premarket approval: a new indication, a design or labeling change, a manufacturing site or process change.
Source: U.S. Food and Drug Administration (FDA), Premarket Approval (PMA) database · Source date: